论文部分内容阅读
目的观察奈达铂联合放疗治疗中晚期鼻咽癌的临床疗效,探讨奈达铂联合放疗治疗中晚期鼻咽癌的可行性。方法将收治的59例患者按随机分组分为观察组与对照组,两组患者均进行放射治疗,在此基础上,观察组予以奈达铂进行化疗,对照组予以顺铂进行化疗,比较两组患者临床疗效及不良反应发生率。结果两组患者均按治疗计划完成放射治疗,对照组1例患者因出现严重过敏反应放弃化疗,观察组患者均按治疗方案完成化疗。观察组与对照组患者临床有效率分别为96.67%与96.43%,两者差异无统计学意义(P>0.05)。观察组患者胃肠道反应的发生率低于对照组,差异具有统计学意义(P<0.05);血小板减低发生率高于对照组(P<0.05);白细胞减低、血红蛋白减低发生率、皮肤黏膜反应发生率与对照组比较差异无统计学意义(P>0.05)。结论奈达铂配合放疗治疗中晚期鼻咽癌近期效果满意,不良反应发生率低于对照组,可在中晚期鼻咽癌的临床治疗中进行推广。
Objective To observe the clinical efficacy of nedaplatin combined with radiotherapy in the treatment of advanced nasopharyngeal carcinoma and to explore the feasibility of nedaplatin combined with radiotherapy in the treatment of advanced nasopharyngeal carcinoma. Methods Fifty-nine patients were randomly divided into observation group and control group. Radiotherapy was performed in both groups. On the basis of this, the observation group was given nedaplatin for chemotherapy, while the control group was given cisplatin for chemotherapy. Group clinical efficacy and incidence of adverse reactions. Results The two groups of patients completed the radiotherapy according to the treatment plan. One patient in the control group gave up chemotherapy because of severe allergic reaction, and the patients in the observation group completed the chemotherapy according to the treatment plan. The clinical effective rates in the observation group and the control group were 96.67% and 96.43% respectively, with no significant difference between the two groups (P> 0.05). The incidence of gastrointestinal reactions in the observation group was lower than that in the control group (P <0.05), the incidence of thrombocytopenia was higher than that in the control group (P <0.05), the incidence of leukopenia, hemoglobin reduction, There was no significant difference in response rate between the two groups (P> 0.05). Conclusion Nedaplatin combined with radiotherapy in the treatment of advanced nasopharyngeal carcinoma with satisfactory results recently, the incidence of adverse reactions is lower than that of the control group, which can be extended in the clinical treatment of advanced nasopharyngeal carcinoma.